SecBot SecBot

RVPH drug pipeline

$0.3504
−0.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±2.0%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
2
1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 3
Time to marketIf approved, brilaroxazine is at least 3-5 years from potential commercialization. RECOVER-2 enrollment is expected to begin in 1H 2027 (subject to financing), followed by a multi-year trial, NDA submission, and FDA review.

brilaroxazine Updated Nov 13

What to watch

The immediate catalyst is FDA feedback on the new brilaroxazine formulation, expected in Q4 2026 (any day now). Positive feedback would clear a path for RECOVER-2 and NDA; negative feedback or a request for more data would likely pressure the stock further. Separately, the company needs to raise additional capital before RECOVER-2 enrollment can begin in 1H 2027, and its OTCQB listing limits financing options.

Bull case
  • The Phase 3 RECOVER trial met its primary endpoint in October 2023, showing statistically significant efficacy in schizophrenia, and the one-year open-label extension data reinforced consistent, wide-spectrum symptom control.
  • Brilaroxazine is a novel serotonin-dopamine stabilizer that may address both positive and negative symptoms of schizophrenia, a key differentiator versus older antipsychotics.
  • The FDA granted Orphan Drug Designation for brilaroxazine in pulmonary arterial hypertension (PAH) in April 2026, opening a second potential market.
Bear case
  • FDA required a second Phase 3 trial (RECOVER-2) in December 2025, which caused the stock to crash ~50% and delayed any NDA submission by years.
  • RECOVER-2 patient enrollment is explicitly contingent on additional financing; with only $17.5M in cash and a ~$3M/quarter burn rate, the company will likely need dilutive equity raises.
  • The stock was delisted from Nasdaq to OTCQB in May 2026, severely limiting liquidity and institutional ownership.
● neutral
Impact
PhasePreclinical
Time to marketUnknown — at least 5-7 years if clinical development begins, given the preclinical stage and the company's constrained financial resources.

RP1208 Updated Sep 12

What to watch

RP1208 is preclinical and has no scheduled clinical or regulatory catalyst in the next 12 months. For RVPH investors, the stock's trajectory depends entirely on the lead asset brilaroxazine (RP5063) and the company's ability to finance its Phase 3 RECOVER-2 trial. RP1208 is not a near-term value driver.

Bull case
  • RP1208 targets a validated triple-reuptake mechanism with potential applications in both depression and obesity, two large markets.
  • Composition-of-matter patents have been granted in the US, Europe, Canada, China, and Japan, providing intellectual property protection.
  • The drug is a new chemical entity discovered in-house, meaning Reviva retains full ownership and upside if successfully developed or partnered.
Bear case
  • RP1208 is preclinical and has not yet entered human trials, the vast majority of preclinical drug candidates never reach the market.
  • Reviva is financially constrained: delisted from Nasdaq to OTCQB, stock at ~$0.54, and only ~$20M in cash, which is primarily allocated to the lead brilaroxazine program.
  • The company's lead asset brilaroxazine faces its own challenges (FDA requested an additional Phase 3 trial), and RP1208 is a distant secondary priority with no announced development timeline.

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Apr 15, 2026brilaroxazineOrphan drug designation+2.0%+8.3%